Cohen Neil Harris 4

4 · Chemomab Therapeutics Ltd. · Filed May 19, 2022

Form 4

Period: 2022-05-18

Directorinterim CEO

Transactions

Award
Option to Purchase American Depositary Shares
2021-04-19+11,884→ 11,884 total
Exercise: $27.26Exp: 2031-04-19→ American Depositary Shares (11,884 underlying)
Purchase
American Depositary Shares
2022-05-18$3.19/sh+2,000$6,380→ 12,409 total
Award
Option to Purchase American Depositary Shares
2022-03-07+6,820→ 6,820 total
Exercise: $3.53Exp: 2032-03-07→ American Depositary Shares (6,820 underlying)
Award
Option to Purchase American Depositary Shares
2021-03-16+688→ 688 total
Exercise: $13.17Exp: 2030-07-15→ American Depositary Shares (688 underlying)

Footnotes (7)

[F1]Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.
[F2]The ADSs are held of record directly by the Phoenix Insurance Company Ltd. (Naftali Neil Cohen) (the "IRA"), which is self-managed by the Reporting Person. The Reporting Person is the sole beneficiary of the IRA and may be deemed to have sole voting and dispositive power with respect to the ADSs held by IRA.
[F3]Includes the previously reported 10,409 ADSs of the Company, as reported by Mr. Neil Cohen on Form 4 filed with the SEC on March 15, 2022.
[F4]No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.
[F5]These options vest and become exercisable in their entirety on March 16, 2023 subject to the Reporting Person's continued service.
[F6]These options vest and become exercisable in equal monthly installments over a 36 month period commencing on March 16, 2021, subject to the Reporting Person's continued service.
[F7]These options vest and become exercisable as follows: 1/3 vested on July 16, 2021, and the remaining options vest on a quarterly basis for the following eight quarters, subject to the Reporting Person's continued service.

Documents

1 file